Physician profile
Daniel Mosallaei
NPI 1568043156
$2,042.27
in general payments reported to CMS, 2019-2025
7 companies · $1,320 in 2025
The $1,320 reported for 2025 was more than what 91% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $722 · 2025: $1,320.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,385 · Travel and Lodging: $503 · Education: $154.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,385.10 |
| Travel and Lodging | $502.81 |
| Education | $154.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,202.61 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $278.24 | 2024-2025 | Dupixent |
| Genzyme Corporation | $243.49 | 2024 | |
| Ucb, INC. | $143.71 | 2025 | Bimzelx |
| Boehringer Ingelheim Pharmaceuticals, INC. | $120.40 | 2025 | Spevigo |
| Galderma Laboratories, L.P. | $30.84 | 2024 | |
| Incyte Corporation | $22.98 | 2025 | Opzelura |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Mosallaei listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.